Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the effect and safety of prucalopride on recovery of gastrointestinal function in patient undergoing major gastrointestinal surgery. The investigators hypothesize that patients who take prucalopride after major gastrointestinal surgery will have shorter duration of postoperative ileus.
Postoperative ileus (POI), an interruption of bowel motility function, virtually occurs in all patients undergoing major gastrointestinal(GI) surgery. This functional impairment persists for a variable duration, usually resolving within 1 day in the small intestine, 1 to 3 days in the stomach and 3 to 5 days in the colon. Therefore, time of return of colonic function is the the major determinant of duration of POI. Attempts to reduce the duration of POI have prompted the implementation of fast track surgery including early removal of the nasogastric tube, early feeding, alvimopan, gum chewing, and prompt ambulation. However, it is still reported to be more than 4-5 days in most of the randomized trial. Therefore, methods specifically aiming at promoting postoperative colon motility may further enhance the GI function recovery, and prucalopride may be one of the options.
Prucalopride, a substituted benzamide with selective 5-HT4 agonist activity, has been shown previously to significant improve colon motility and transit, but it only has mild effect on gastric or small bowel transit. The drug is well tolerated with no significant adverse effects. Recently, prucalopride has been approved in Europe and America for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. However, its usage in the postoperative period has not been tested. This study will test the ability and safety of prucalopride given 24hrs after GI surgery to hasten the recovery of GI function.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prucalopride | Experimental | Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment |
|
| Placebo | Placebo Comparator | Vitamin C, 50mg, tablet |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prucalopride | Drug | Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time to defaecation, measured in hours, from the time the surgery ends till the first observed passage of stool | up to 30 days after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Time of first passing flatus reported by the patients(hours) | up to 30 days after surgery | |
| Time to resume solid diet or total enteral nutrition(TEN)(days) | up to 30 days after surgery | |
| Measure | Description | Time Frame |
|---|---|---|
| Whole blood white blood cell(WBC) count on postoperative day 1 and 3 | whole blood white blood cell (WBC) count(*109/L) | postoperative day 1 and 3 |
| Whole blood neutrophil percentage on postoperative day 1 and 3 |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jianfeng Gong, MD | Department of general surgery,Jinling hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University | Nanjing | Jiangsu | 210002 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26880227 | Derived | Gong J, Xie Z, Zhang T, Gu L, Yao W, Guo Z, Li Y, Lu N, Zhu W, Li N, Li J. Randomised clinical trial: prucalopride, a colonic pro-motility agent, reduces the duration of post-operative ileus after elective gastrointestinal surgery. Aliment Pharmacol Ther. 2016 Apr;43(7):778-89. doi: 10.1111/apt.13557. Epub 2016 Feb 15. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005767 | Gastrointestinal Diseases |
| ID | Term |
|---|---|
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C406662 | prucalopride |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | Vitamin, 50mg, tablet. |
|
| Length of postoperative hospital stay (LOS)(days) |
| participants will be followed for the duration of postoperative hospital stay, an expected average of 8 days |
| Overall post-operative complication rate defined according to the Clavien-Dindo Classification | up to 30 days after surgery |
| Overall cost (RMB) | participants will be followed for the duration of postoperative hospital stay, an expected average of 8 days |
| Pain scores on visual analogue scale (from 0 which implies no pain at all, to 10 which implies the worst pain imaginable) on the first 3 postoperative days and postoperative analgesic requirement (number of doses on 50-mg Pethidine) | up to postoperative day 3 |
| Time to walk independently(days) | up to 30 days after surgery |
| Hospital Readmission Rates Post 30-day Discharge | up to 30 days after discharge |
| Length of postoperative ICU stay (days) | up to 30 days after surgery |
| Incidence of adverse events related to drug usage | Diarrhoea,Flatulence,Nausea,Abdominal pain,Headaches,Menstrual disorder,Dizziness ,Skeletal pain,ECG nodal arrhythmia | up to 7 days after drug usage |
| Reinsertion of nasogastric tube | up to 30 days after surgery |
neutrophil percentage(%)
| postoperative day 1 and 3 |
| Whole blood platelet level on postoperative day 1 and 3 | platelet level(*109/L) | postoperative day 1 and 3 |
| Serum C-reactive protein(CRP) level on postoperative day 1 and 3. | CRP level(mg/dL) | postoperative day 1 and 3 |
| Serum interleukin-6(IL-6) level on postoperative day 1 and 3. | IL-6(pg/ml) | postoperative day 1 and 3 |
| Serum procalcitonin(PCT) level on postoperative day 1 and 3. | PCT(ug/L) | postoperative day 1 and 3 |